<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49020">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468063</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-001</org_study_id>
    <nct_id>NCT02468063</nct_id>
  </id_info>
  <brief_title>To Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock</brief_title>
  <official_title>A Prospective Study to Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The consecutive patients admitted to Intensive care unit of Hepatology department of ILBS
      and full filling all the eligibility criteria will be enrolled in 1:1 ration by the process
      of randomization.- The study is an open level study. The investigators will strictly follow
      the randomization table to give therapy as per the intervention arm.

        -  Intervention:-the therapeutic intervention is vasopressor i.e. noradrenaline alone and
           terlipressin along with noradrenaline to maintain the MAP &gt;65mm Hg.

        -  Intervention arm

             -  Arm (A) - Noradrenaline

             -  Arm (B) - Noradrenaline + low dose terlipressin
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target MAP (Mean Arterial Pressure) &gt;65 mm Hg at 6 hrs</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintenance of target MAP (Mean Arterial Pressure)</measure>
    <time_frame>2 days</time_frame>
    <description>MAP is Mean Arterial pressure SVR is Sustained Virologic Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microcirculation (lactate level, Lactate clearance, SCVO2, ABG-VBG Pco2 difference),</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue perfusion (lactate level, Lactate clearance, SCVO2, ABG-VBG Pco2 difference),</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on - AKI (Acute kidney Injury),</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on variceal bleed</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on rebound hypotension</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on organ failure</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of adverse events.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR (Sustained Virologic Response) â‰¥600 at 48 hrs</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Cirrhosis With Septic Shock</condition>
  <arm_group>
    <arm_group_label>Noradrenaline + low dose terlipressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Noradrenaline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose terlipressin</intervention_name>
    <description>Terlipressin-2mg (low dose )</description>
    <arm_group_label>Noradrenaline + low dose terlipressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Noradrenaline</intervention_name>
    <description>Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min</description>
    <arm_group_label>Noradrenaline + low dose terlipressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Noradrenaline</intervention_name>
    <description>Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min</description>
    <arm_group_label>Noradrenaline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 yr

          -  Cirrhosis with septic shock not responding to fluid resuscitation within 2 hrs.

        Exclusion Criteria:

          -  ECG (ElectroCardiography)changes at presentation which exclude the use of vasopressin
             analouges

          -  Cardiac dysfunction ( valvular heart disease, coronary artery disease)

          -  Acute mesenteric ischemia (confirmed or suspected) or vasospastic diathesis (e.g.
             Reynaud's syndrome or related diseases).

          -  Pregnancy

          -  Acute GI bleed

          -  No Consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikash Prakash, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vikash Prakash, MD</last_name>
    <phone>+91-46300000</phone>
    <email>vp_vmmc@yahoo.co.in</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 1, 2017</lastchanged_date>
  <firstreceived_date>May 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
